P1 Circulating adiponectin levels as a predictive factor of breast cancer in a double-blind 2×2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention

A. Guerrieri Gonzaga; S. Gandini; H. Johansson; D. Macis; P. Magni; E. Dozio; M. Lazzeroni; M. Gulisano; A. Decensi; B. Bonanni

doi:10.1016/s1359-6349(10)70759-x

P1 Circulating adiponectin levels as a predictive factor of breast cancer in a double-blind 2×2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70759-x ◽

2010 ◽

Vol 8 (2) ◽

pp. 9

Author(s):

A. Guerrieri Gonzaga ◽

S. Gandini ◽

H. Johansson ◽

D. Macis ◽

P. Magni ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Prevention ◽

Phase Ii ◽

Predictive Factor ◽

Low Dose ◽

Phase Ii Trial ◽

Breast Cancer Prevention ◽

Double Blind

Download Full-text

Abstract A61: Circulating adiponectin levels as a predictive factor of breast cancer in a double-blind 2x2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention

10.1158/1940-6207.prev-10-a61 ◽

2010 ◽

Author(s):

Guerrieri-Gonzaga Aliana ◽

Sara Gandini ◽

Harriet Johansson ◽

Debora Macis ◽

Paolo Magni ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Prevention ◽

Phase Ii ◽

Predictive Factor ◽

Low Dose ◽

Phase Ii Trial ◽

Breast Cancer Prevention ◽

Double Blind

Download Full-text

A randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention of high-risk premenopausal women

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1503 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1503-1503

Author(s):

A. Decensi ◽

C. Robertson ◽

A. Guerrieri-Gonzaga ◽

D. Serrano ◽

M. Cazzaniga ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Prevention ◽

Low Dose ◽

Premenopausal Women ◽

Breast Cancer Prevention ◽

Double Blind

Download Full-text

Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps114 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS114-TPS114

Author(s):

E. Andreopoulou ◽

A. P. Chen ◽

J. Zujewski ◽

M. Kim ◽

D. L. Hershman ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Double Blind Placebo ◽

Metronomic Cyclophosphamide

Download Full-text

OT3-01-17: Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Low-Dose Metronomic Cyclophosphamide Alone or in Combination with Veliparib (ABT-888) in Chemotherapy-Resistant ER and/or PR-Positive, HER2/neu-Negative Metastatic Breast Cancer: New York Cancer Consortium Trial P8853.

10.1158/0008-5472.sabcs11-ot3-01-17 ◽

2011 ◽

Author(s):

E Andreopoulou ◽

AP Chen ◽

JA Zujewski ◽

K Kalinsky ◽

L Vahdat ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Double Blind Placebo ◽

Metronomic Cyclophosphamide

Download Full-text

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

European Journal of Cancer ◽

10.1016/j.ejca.2015.10.012 ◽

2016 ◽

Vol 53 ◽

pp. 144-154 ◽

Cited By ~ 19

Author(s):

Konstantinos Tryfonidis ◽

Gul Basaran ◽

Jan Bogaerts ◽

Marc Debled ◽

Luc Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

European Organisation ◽

Hormone Receptor Positive

Download Full-text

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug

Breast Cancer Research ◽

10.1186/bcr3233 ◽

2012 ◽

Vol 14 (5) ◽

Cited By ~ 36

Author(s):

Matteo Lazzeroni ◽

Davide Serrano ◽

Barbara K Dunn ◽

Brandy M Heckman-Stoddard ◽

Oukseub Lee ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Prevention ◽

Low Dose ◽

Breast Cancer Prevention

Download Full-text

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii

Download Full-text

Abstract C124: Breast density and metabolic risk factors: Cross-sectional analysis of the baseline data from a phase II breast cancer prevention trial

10.1158/1538-7755.disp18-c124 ◽

2020 ◽

Author(s):

Jesse Trujillo ◽

Edgar Tapia ◽

Diana Villa-Guillen ◽

Pavani Chalasani ◽

Cynthia Thomson ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Cancer Prevention ◽

Phase Ii ◽

Breast Density ◽

Breast Cancer Prevention ◽

Metabolic Risk ◽

Cross Sectional ◽

Breast Cancer Prevention Trial ◽

Sectional Analysis

Download Full-text

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08

European Journal of Cancer ◽

10.1016/j.ejca.2015.03.016 ◽

2015 ◽

Vol 51 (10) ◽

pp. 1212-1220 ◽

Cited By ~ 22

Author(s):

Khalil Zaman ◽

Ralph Winterhalder ◽

Christoph Mamot ◽

Ursula Hasler-Strub ◽

Christoph Rochlitz ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Inhibitor Therapy ◽

Double Blind ◽

Aromatase Inhibitor Therapy

Download Full-text

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.618 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 618-618

Author(s):

T. Ueno ◽

N. Masuda ◽

S. Kamigaki ◽

T. Morimoto ◽

S. Nakamura ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Estrogen Receptor ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Circulating Endothelial Cells ◽

Multicenter Phase ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text